PROKIDNEY CORP.

We are a late-clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advanced chronic kidney disease ( CKD ) and diabetes. Our approach seeks to redefine the treatment of CKD, shifting the emphasis away from management of kidney failure to the preservation of kidney function. Our lead product candidate, rilparencel, is the only cell therapy in Phase 3 clinical study for the treatment of advanced CKD and type 2 diabetes. Rilparencel is a product that includes autologous Selected Renal Cells ( SRC ) prepared from a patient’s own (autologous) kidney cells. The SRC are formulated as rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure. Because rilparencel is a personalized product composed of cells prepared from a patient’s own kidney, there is no need for treatment with immunosuppressive therapies that are required during a patient’s lifetime when a patient receives a kidney transplant from another (allogeneic) donor. Our technology works by expanding and selecting kidney cells of a patient to preserve kidney function that is being lost due to chronic disease. Our process begins when a small piece (biopsy) of a patient’s diseased kidney is sent to our manufacturing facility. We process tissue taken from the biopsy and isolate SRC that are formulated into a personalized product for reinjection into the damaged kidney(s).